Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 9 Years
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 18
States / cities: Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more

Conditions: Type 2 Diabetes, End Stage Renal Disease
Interventions: Placebo, Sitagliptin; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions: Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more

Conditions: Gastric Cancer, Adenocarcinoma
Interventions: ramucirumab, Placebo, Best Supportive Care (BSC); Biological · Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Bakersfield, California • La Jolla, California • Redlands, California + 11 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Placebo matching Olodaterol, Olodaterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 94
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more

Conditions: Celiac Disease
Interventions: TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar; Drug · Dietary Supplement
Lead sponsor: Takeda; Industry
Eligibility: 12 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Paradise Valley, Arizona + 52 more

Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy; Procedure · Other · Drug + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 242
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more

Conditions: Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
Interventions: Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires; Drug · Behavioral · Other
Lead sponsor: Brian Anderson, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Plaque Psoriasis
Interventions: TAK-279, Placebo, Apremilast; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 24 more

Conditions: Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions: quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy; Drug · Behavioral
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Lung Cancer, Non-Small Cell
Interventions: Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Newark, Delaware • Springfield, Illinois • Rochester, Minnesota + 5 more

Conditions: Depression, Dementia
Interventions: Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alcoholism
Interventions: acamprosate; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, Ceftriaxone, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder, Treatment Resistant Depression
Interventions: Nitrous oxide gas for inhalation, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Orthostatic Hypotension, Parkinson's Disease
Interventions: Droxidopa, Placebo; Drug · Other
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 60
States / cities: Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more

Conditions: PONV
Interventions: APD421- Amisulpride for IV injection, Placebo; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
Interventions: Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP); Drug
Lead sponsor: Richard Dart, MD, PhD; Other
Eligibility: 10 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma, Precancerous Condition
Interventions: vandetanib, placebo, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, pharmacological study; Drug · Other · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Binge Eating, Depression
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Interventions: MagicTouch PTA Sirolimus drug coated balloon, Placebo balloon angioplasty; Device
Lead sponsor: Concept Medical Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 29
States / cities: Scottsdale, Arizona • Los Angeles, California • Clearwater, Florida + 22 more

Conditions: Healthy Participants
Interventions: AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Cystic Fibrosis Related Bone Disease
Interventions: Estradiol 2 mg, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes (T2D)
Interventions: NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 30 more

Search by objective public record fields.

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Ketamine-assisted Therapy for Advanced GI Cancer

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Quetiapine for the Reduction of Cocaine Use

A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

Acamprosate: Genes Associated With Response

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

Antidepressant Effects of Nitrous Oxide

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

US Phase III Study of APD421 in PONV

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression

Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

Pilot E2 for Hypogonadal Women With CFBD

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes